Hidradenitis suppurativa (HS) highlights from AAD 2025 include studies of HS patients' risk for cardiovascular disease or ...

Hidradenitis suppurativa treatment experiences vary widely among patients; a new study highlights the need for personalised care and shared decision-making.

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

Study authors examined the relationship between the use of combined oral contraceptives and the onset of hidradenitis suppurativa.

Certain soaps and other skin care products may irritate hidradenitis suppurativa (HS), whereas others can help manage the condition and its symptoms. HS is a chronic skin condition that causes ...

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

—The results of a new survey indicate that many patients with hidradenitis suppurativa (HS)—especially Blacks and Hispanics—say that the color of their skin may indeed play a role in how ...

One key opportunity for growth of the hidradenitis Suppurativa market is the untapped potential found in emerging countries with growing healthcare infrastructure and treatment availability. This ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from povorcitinib treatment, Incyte announced in a press release.